Australian medical technology innovator Echo IQ (ASX: EIQ) has strengthened its commercial ties with the Mayo Clinic, announcing an expanded agreement to distribute its AI-driven heart failure solution, EchoSolv HF.
The revised framework positions the Mayo Clinic to act as a primary reseller and distributor of the technology across its extensive healthcare network and through the Mayo Clinic Platform – Solutions Studio Program.
The partnership now includes more favourable commercial terms and an automatic renewal clause that extends the potential collaboration to six years, signalling a robust long-term commitment between the two entities.
The strategic expansion follows a successful validation study where EchoSolv HF demonstrated a remarkable sensitivity of 99.5% and a specificity of 91.1% in identifying heart failure patients.
While the results await final FDA review, the company has already lodged a 510(k) premarket notification.
Once cleared, the distribution through the Mayo Clinic Platform will provide a scalable pathway into over 80 external partner hospitals, addressing a critical gap in US healthcare.
Currently, heart failure affects approximately 6.7 million Americans, yet nearly half of all cases remain inaccurately diagnosed.
Echo IQ aims to unlock a market opportunity while improving outcomes for the one in four Americans expected to develop heart failure in their lifetime.
At the time of reporting, Echo IQ’s share price was $0.72.